Abstract
BACKGROUND: Although coronary artery bypass graft surgery (CABG) is known to reduce angina, previous studies have suggested that anti-anginal medication use is not significantly reduced after CABG. However, it is unclear how functional testing results have an impact on anti-anginal medication prescription patterns. OBJECTIVES: To determine whether post-CABG functional testing results impact prescription patterns of anti-anginal medication during the 12 months after CABG. METHODS: The Routine versus Selective Exercise Treadmill Testing after Coronary Artery Bypass Graft Surgery (ROSETTA-CABG) Registry is a prospective, multicenter study. We examined anti-anginal medication use (beta blockers, calcium channel blockers and nitrates) at discharge and at 12 months post-CABG with respect to functional testing results among 392 patients. RESULTS: Among the 392 patients, 146 had at least one functional test over the 12-month follow up period. Among the 146 patients, 17% had positive functional tests, 69% had negative tests, and 14% had indeterminate tests. Both beta blocker and calcium channel blocker use did not increase from discharge to 12 months following a positive test (N ≤ 25) (84% vs. 80%; p ≤ NS; 16% vs. 16%; p ≤ NS), while nitrate use increased seven-fold (4% vs. 28%; p ≤ 0.03). However, following a negative test (N ≤ 100), beta blocker use only decreased modestly (85% vs. 70%; p ≤ 0.01), while both calcium channel blocker and nitrate use were unchanged (30% vs. 20%; p ≤ NS; 4% vs. 6%; p ≤ NS, respectively). Following an indeterminate test (N ≤ 21), anti-anginal medication use was unchanged (p ≤ NS for all 3 classes of medication). CONCLUSION: The use of anti-anginal medication is only modestly reduced after CABG, and functional testing results during the first year post-CABG do not have a strong impact on prescription patterns of anti-anginal agents.
| Original language | English |
|---|---|
| Pages (from-to) | 278-282 |
| Number of pages | 5 |
| Journal | Journal of Invasive Cardiology |
| Volume | 18 |
| Issue number | 6 |
| State | Published - Jun 2006 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
Impact of functional testing results on prescription patterns of anti-anginal medication after coronary artery bypass graft surgery : Results from the ROSETTA-CABG Registry. / Wou, Karen; Nguyen, Hiep; Duerr, Robert; Del Core, Michael; Fourchy, Dominique; Huynh, Thao; Lader, Ellis; Rogers, Felix J.; Chaudhry, Rashid; Pilote, Louise; Eisenberg, Mark J.
In: Journal of Invasive Cardiology, Vol. 18, No. 6, 06.2006, p. 278-282.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of functional testing results on prescription patterns of anti-anginal medication after coronary artery bypass graft surgery
T2 - Results from the ROSETTA-CABG Registry
AU - Wou, Karen
AU - Nguyen, Hiep
AU - Duerr, Robert
AU - Del Core, Michael
AU - Fourchy, Dominique
AU - Huynh, Thao
AU - Lader, Ellis
AU - Rogers, Felix J.
AU - Chaudhry, Rashid
AU - Pilote, Louise
AU - Eisenberg, Mark J.
PY - 2006/6
Y1 - 2006/6
N2 - BACKGROUND: Although coronary artery bypass graft surgery (CABG) is known to reduce angina, previous studies have suggested that anti-anginal medication use is not significantly reduced after CABG. However, it is unclear how functional testing results have an impact on anti-anginal medication prescription patterns. OBJECTIVES: To determine whether post-CABG functional testing results impact prescription patterns of anti-anginal medication during the 12 months after CABG. METHODS: The Routine versus Selective Exercise Treadmill Testing after Coronary Artery Bypass Graft Surgery (ROSETTA-CABG) Registry is a prospective, multicenter study. We examined anti-anginal medication use (beta blockers, calcium channel blockers and nitrates) at discharge and at 12 months post-CABG with respect to functional testing results among 392 patients. RESULTS: Among the 392 patients, 146 had at least one functional test over the 12-month follow up period. Among the 146 patients, 17% had positive functional tests, 69% had negative tests, and 14% had indeterminate tests. Both beta blocker and calcium channel blocker use did not increase from discharge to 12 months following a positive test (N ≤ 25) (84% vs. 80%; p ≤ NS; 16% vs. 16%; p ≤ NS), while nitrate use increased seven-fold (4% vs. 28%; p ≤ 0.03). However, following a negative test (N ≤ 100), beta blocker use only decreased modestly (85% vs. 70%; p ≤ 0.01), while both calcium channel blocker and nitrate use were unchanged (30% vs. 20%; p ≤ NS; 4% vs. 6%; p ≤ NS, respectively). Following an indeterminate test (N ≤ 21), anti-anginal medication use was unchanged (p ≤ NS for all 3 classes of medication). CONCLUSION: The use of anti-anginal medication is only modestly reduced after CABG, and functional testing results during the first year post-CABG do not have a strong impact on prescription patterns of anti-anginal agents.
AB - BACKGROUND: Although coronary artery bypass graft surgery (CABG) is known to reduce angina, previous studies have suggested that anti-anginal medication use is not significantly reduced after CABG. However, it is unclear how functional testing results have an impact on anti-anginal medication prescription patterns. OBJECTIVES: To determine whether post-CABG functional testing results impact prescription patterns of anti-anginal medication during the 12 months after CABG. METHODS: The Routine versus Selective Exercise Treadmill Testing after Coronary Artery Bypass Graft Surgery (ROSETTA-CABG) Registry is a prospective, multicenter study. We examined anti-anginal medication use (beta blockers, calcium channel blockers and nitrates) at discharge and at 12 months post-CABG with respect to functional testing results among 392 patients. RESULTS: Among the 392 patients, 146 had at least one functional test over the 12-month follow up period. Among the 146 patients, 17% had positive functional tests, 69% had negative tests, and 14% had indeterminate tests. Both beta blocker and calcium channel blocker use did not increase from discharge to 12 months following a positive test (N ≤ 25) (84% vs. 80%; p ≤ NS; 16% vs. 16%; p ≤ NS), while nitrate use increased seven-fold (4% vs. 28%; p ≤ 0.03). However, following a negative test (N ≤ 100), beta blocker use only decreased modestly (85% vs. 70%; p ≤ 0.01), while both calcium channel blocker and nitrate use were unchanged (30% vs. 20%; p ≤ NS; 4% vs. 6%; p ≤ NS, respectively). Following an indeterminate test (N ≤ 21), anti-anginal medication use was unchanged (p ≤ NS for all 3 classes of medication). CONCLUSION: The use of anti-anginal medication is only modestly reduced after CABG, and functional testing results during the first year post-CABG do not have a strong impact on prescription patterns of anti-anginal agents.
UR - http://www.scopus.com/inward/record.url?scp=33747119426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747119426&partnerID=8YFLogxK
M3 - Article
C2 - 16751682
AN - SCOPUS:33747119426
VL - 18
SP - 278
EP - 282
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
SN - 1042-3931
IS - 6
ER -